Amyloidosis: a rare cause of severe acute liver failure

Fernandes, Daniel Alvarenga; Assis-Mendo�a, Guilherme Rossi; Costa, Larissa Bastos Eloy da; Freitas, Leandro Luiz Lopes de; Boin, Ilka de Fátima Ferreira Santana; Reis, Fabiano

doi:10.17235/reed.2023.9598/2023

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To enhance our understanding of the relationship between ferroptosis and MSCs, we employed H-uc MSCs for intervention in CCL 4 -treated mice. Hepatomegaly is the most common clinical symptom in patients with acute liver disease [ 34 , 35 ]. Gross examination showed that under the treatment of MSCs, the liver surface of mice changed from gray-white to a ruddy hue, and the size of the liver went from large to small.…”

Section: Resultsmentioning

confidence: 99%

Human umbilical cord mesenchymal stem cells protect against ferroptosis in acute liver failure through the IGF1-hepcidin-FPN1 axis and inhibiting iron loading

Cheng,

Shi,

et al. 2024

ABBS

View full text Add to dashboard Cite

Acute liver failure (ALF) is a significant global issue with elevated morbidity and mortality rates. There is an urgent and pressing need for secure and effective treatments. Ferroptosis, a novel iron-dependent regulation of cell death, plays a significant role in multiple pathological processes associated with liver diseases, including ALF. Several studies have demonstrated that mesenchymal stem cells (MSCs) have promising therapeutic potential in the treatment of ALF. This study aims to investigate the positive effects of MSCs against ferroptosis in an ALF model and explore the underlying molecular mechanisms of their therapeutic function. Our results show that intravenously injected MSCs protect against ferroptosis in ALF mouse models. MSCs decrease iron deposition in the liver of ALF mice by downregulating hepcidin level and upregulating FPN1 level. MSCs labelled with Dil are mainly observed in the hepatic sinusoid and exhibit colocalization with the macrophage marker CD11b fluorescence. ELISA demonstrates a high level of IGF1 in the CCL 4 +MSC group. Suppressing the IGF1 effect by the PPP blocks the therapeutic effect of MSCs against ferroptosis in ALF mice. Furthermore, disruption of IGF1 function results in iron deposition in the liver tissue due to impaired inhibitory effects of MSCs on hepcidin level. Our findings suggest that MSCs alleviate ferroptosis induced by disorders of iron metabolism in ALF mice by elevating IGF1 level. Moreover, MSCs are identified as a promising cell source for ferroptosis treatment in ALF mice.

show abstract

Section: Resultsmentioning

confidence: 99%